Jeffrey Smith, MD
Psychiatry · Greenville, SCNPI 1932147188
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 483 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 483 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$855
- Takeda Pharmaceuticals U.S.A., Inc.$839
- Lundbeck LLC$778
- Tris Pharma Inc$459
- plus $3K from 22 others
Across 3 payments — averaging $485.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Food & beverage$8,47799%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 70 | $1,190 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $1,097 |
| AbbVie(2 entities) | 70 | $855 |
| Takeda Pharmaceuticals U.S.A., Inc. | 51 | $839 |
| Lundbeck LLC | 37 | $778 |
| Tris Pharma Inc | 21 | $459 |
| Axsome Therapeutics, Inc. | 17 | $385 |
| Corium, LLC | 19 | $341 |
| Bausch Health US, LLC | 15 | $294 |
| Neos Therapeutics, LP | 19 | $290 |
| Alkermes, Inc. | 13 | $285 |
| Teva Pharmaceuticals USA, Inc. | 15 | $276 |
| Vanda Pharmaceuticals Inc. | 11 | $225 |
| Johnson & Johnson | 13 | $225 |
| Ironshore Pharmaceuticals Inc. | 9 | $159 |
| Eisai Inc. | 14 | $144 |
| Noven Therapeutics, LLC | 6 | $124 |
| Merck | 6 | $97 |
| Avanir Pharmaceuticals, Inc. | 5 | $82 |
| Almatica Pharma LLC | 4 | $70 |
| Idorsia Pharmaceuticals US Inc | 4 | $62 |
| Adlon Therapeutics L.p. | 3 | $48 |
| Neurocrine Biosciences, Inc. | 3 | $46 |
| Harmony Biosciences LLC | 2 | $43 |
| Tonix Medicines, Inc. | 2 | $40 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Shire North American Group Inc | 2 | $26 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
How this compares
$8,524 in reported general payments places this provider in the 90th percentile of 624 psychiatry providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 24 | $155,824 |
| CaplytaLumateperone Tosylate | 46 | $81,407 |
| VraylarCariprazine Hcl | 29 | $56,844 |
| RexultiBrexpiprazole | 25 | $38,187 |
| TrintellixVortioxetine Hydrobromide | 41 | $32,896 |
| Duloxetine Hcl | 657 | $20,076 |
| BelsomraSuvorexant | 32 | $14,007 |
| Ziprasidone Hcl | 157 | $10,111 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 382 | $9,482 |
| Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl | 29 | $9,003 |
| Quetiapine Fumarate | 619 | $8,965 |
| Asenapine Maleate | 35 | $8,765 |
| Methylphenidate ErMethylphenidate Hcl | 57 | $8,538 |
| Lamotrigine | 609 | $8,032 |
| Mirtazapine | 431 | $7,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $276 | $155,82424 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,097 | $81,40746 claims |
| AbbVieVraylar | $855 | $56,84429 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,190 | $38,18725 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $839 | $37,42353 claims |
| MerckBelsomra | $97 | $14,00732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 624 psychiatry providers in South Carolina.
Other psychiatry in Greenville
- Jeffrey StephensGreenville$195K
- Robert RichardsGreenville$142K
- Lisa WischhusenGreenville$14K
- Lauren LevyGreenville$7K
- Brittany AlbrightMount Pleasant$691K
- Veronica RidpathFlorence$364K
- Jagdish ShahRock Hill$320K
- Ricardo FermoCharleston$262K
- John DewittAiken$221K
- Nikunjkumar ModiFlorence$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.